Regeneron Pharmaceuticals (NASDAQ: REGN) 주식에 투자하기

Regeneron Pharmaceuticals (REGN ) (NASDAQ: REGN) 은 뉴욕에 본사를 둔 제약 회사입니다. 30년 이상의 경험을 바탕으로, 회사는 연구 및 개발 역량을 활용하여 수많은 사람들의 삶을 변화시킨 약물을 신속하게 시장에 출시할 수 있었습니다. 회사가 개발한 혁신은 약물 개발 일정을 간소화하여 비용 효율성을 높이고 약물을 시장에 내놓는 비용을 낮추었습니다. 회사는 연구 및 개발 분야에서 계속 활발히 활동하며 최신 과학 혁신을 주시하고 장기 성장에 활용할 방법을 모색하고 있습니다. 

Regeneron Pharmaceuticals (REGN)은 무엇인가요?

Founded in 1988, the original focus of Regeneron’s pharmaceutical research was on the regeneration of brain neurons to treat patients with Huntington disease, Alzheimer disease and Parkinson disease. Four years after establishment, their first drug began clinical trials. While the original drug did not pass these trials, Regeneron has since expanded their research focus to a number of other areas. After two decades of trial and error, the company’s first drug ARCALYST entered the market in the early 2000s. The company now employs close to 9,000 people worldwide and has eight FDA approved treatments on the market today. Their portfolio covers a wide range of medicines, covering allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.
Co-founder George D. Yancopoulos is a scientist by training and was listed as the primary researcher for 6 of the 8 approved drugs Regeneron has brought to market. Despite his roles as President and Chief Scientific Officer, Yancopoulos remains highly involved in the research and development side of the company. Through his continued work, Yancopoulos became the 11th most cited scientist in the 1990s, and many of the methods and techniques used in pharmaceutical research today is a direct result of his research.

Regeneron Pharmaceuticals (REGN)은 왜 중요한가요?

Regeneron’s research and development lifecycle greatly benefit from the ‘Velocisuite’ technology developed by the company in 2003. Through the use of this suite of tools, innovative and accurate results during all phases of the drug trial process are made possible. This suite of technology began being developed in 2003 and includes VeolciGene, VeolciMouse, and VeolciHum.Together, this suite of tools allows for rapid manipulation and replication of the genetic material of lab mice. By doing so, different genetic disorders can be reproduced in mass, allowing for fully-human antibodies to be produced in mice. These factors are highly beneficial for drug testing, allowing for an extremely accurate result that mirrors the impact of therapeutics in humans. The development of mice with genetic compositions similar to humans allowed the company to 약물 개발 일정에서 몇 개월을 단축.

More recently, the company received significant attention for its development of a COVID-19 treatment. Using Velocisuite and other technology, Regeneron was given $450 million by the Department of Health and Human Services to develop an antibody treatment for the virus as part of the US government’s Operation Warp Speed. The treatment, known as REGN-COV2, was given emergency use authorization by the FDA. Regeneron received significant media attention when it was reported that REGN-COV2 was given to President Donald Trump when he was undergoing treatment for his COVID-19 diagnosis. The treatment is very similar to the one developed by the company during the Ebola pandemic. A similar cocktail of drugs given to Ebola patients has led to a nearly 90% survival rate if given during the early days of infection.

Regeneron Pharmaceuticals (REGN) 전망

The company has several drugs at different phases of the FDA trial process. In total, there are 31 drugs produced in-house by Regeneron that are currently in either Stage 1, 2, or 3 of clinical trials. These trials include 8,400 patients in over 53 countries. While it is impossible to predict which are going to be approved, the in-house research capabilities of the company have a solid track record of creating products that make it to market. The company reinvests an impressive 30% of annual revenues back into research and development. This share of revenue is in line with industry giants such as Pfizer (PFE ) and signals a serious commitment to continual growth through the diversification of product offerings With this foresight, the company is consistently ahead of the curve and has the ability to bring more and more products to market.
Regeneron’s approach to drug development is unique and has many benefits. Perhaps most important to their approach is the Regeneron Genetics Center, which opened in 2013 and has already sequenced the genomes of over 1 million people. This work has made Regeneron the holder of one of the largest genetic databases in the world. Through research studies and consenting volunteers, Regeneron collects genetic information, anonymizes it, and then uses their analytical software to look at the genetic traits. Once the data has been analyzed, the company can then use these genetic sequences in their drug research. Understanding the importance genetic sequencing will have in the future of drug testing and development, Regeneron has also been collaborating with major drugmakers such as Pfizer and AstraZeneca (AZN ) to fund global research initiatives aimed at speeding up and improving genetic sequencing technology. The goal of this collaboration is to create efficiencies in research, leading to more advancements in drug development and discovery, and ultimately, improved human health.

Regeneron Pharmaceuticals (REGN) 주식을 어디서 구매할 수 있나요?

A broker that we recommend is Firstrade.

Firstrade는 투자자들이 재정적 미래를 통제할 수 있도록 돕는 다양한 투자 상품과 도구를 제공하는 선도적인 온라인 중개 회사입니다. 1985년 설립 이래로 Firstrade는 높은 가치와 품질의 서비스를 제공하기 위해 노력해 왔습니다.

고유의 거래 기술, 직관적인 사용자 인터페이스, 뛰어난 고객 서비스 및 모바일 애플리케이션을 결합한 Firstrade는 모든 투자 요구를 충족시키는 포괄적인 솔루션을 제공합니다. Firstrade는 FINRA/SIPC 회원입니다.

요약

Regeneron은 연구 및 개발에 대한 확고한 투자를 약속한 제약 회사입니다. 이러한 약속을 통해 업계에서 독특한 다양한 접근 방식과 방법을 만들어냈습니다. 이러한 발전은 치료제의 지속적인 파이프라인이 시장에 도달하도록 했습니다. 유전 시퀀싱을 약물 개발 접근 방식으로 지속적으로 집중함에 따라, 시간이 지남에 따라 기술이 개선되어 제약 산업에서 가장 혁신적인 기업 중 하나로서의 입지를 더욱 확고히 할 것입니다. 한국어.